BrainsWay reported second-quarter 2026 revenue of $17.1 million, up 35% from $12.6 million a year earlier. Adjusted EBITDA was $3.5 million (20% margin) and net income was $2.7 million. The company shipped a record 125 Deep TMS systems, up 42%, bringing the installed base to roughly 1,949 systems.
Remaining performance obligations, mostly from system leases, reached $80.4 million. Full-year 2026 revenue guidance was raised from $66-68 million to $68-70 million, with adjusted EBITDA guidance of $13-14 million.
The release also highlighted expanding insurer coverage for the SWIFT accelerated protocol, real-world PTSD and depression data, and first prospective 12-month durability data for SWIFT. For patients, a growing installed base generally means more clinics able to offer Deep TMS.
Source
Reporting based on coverage from BrainsWay (via Stock Titan). This article is editorial summary intended for general information; it is not medical advice.
